Glucagon-Like Peptide-1 Receptor
"Glucagon-Like Peptide-1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).
| Descriptor ID |
D000067757
|
| MeSH Number(s) |
D12.776.543.750.695.021.500 D12.776.543.750.750.360.100.500
|
| Concept/Terms |
Glucagon-Like Peptide-1 Receptor- Glucagon-Like Peptide-1 Receptor
- Glucagon Like Peptide 1 Receptor
- Peptide-1 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-1
- GLP-1R Receptor
- GLP 1R Receptor
- Receptor, GLP-1R
- GLP1R Protein
- Protein, GLP1R
- GLP-1 Receptor
- GLP 1 Receptor
- Receptor, GLP-1
- GLP1R Receptor
- Receptor, GLP1R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-1 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-1 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-1 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 14 | 10 | 24 |
| 2018 | 12 | 14 | 26 |
| 2019 | 6 | 5 | 11 |
| 2020 | 0 | 2 | 2 |
| 2021 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide-1 Receptor" by people in Profiles.
-
Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021 Sep; 179:109031.
-
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
-
Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection. Int J Mol Sci. 2021 Jul 16; 22(14).
-
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. Diabetes Care. 2021 07; 44(7):1564-1572.
-
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes Obes Metab. 2021 06; 23(6):1397-1401.
-
Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe? Clin Obes. 2021 Apr; 11(2):e12439.
-
Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany. Diabetes Obes Metab. 2021 04; 23(4):910-915.
-
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? J Diabetes Complications. 2020 12; 34(12):107723.
-
Dissecting the interaction between COVID-19 and diabetes mellitus. J Diabetes Investig. 2020 Sep; 11(5):1104-1114.
-
Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovasc Diabetol. 2020 07 22; 19(1):115.